PRTN3 and alpha 1-antitrypsin deficiency: Measuring NE and PR3 activities as a treatment outcome is particularly important when investigating the treatment effects of chronic neutrophilic diseases, such as AATD, where these enzymes are considered primary drivers of the disease process.